On March 6, 2022 Chimeric Therapeutics Presented that Corporate Presentation (Press release, Chimeric Therapeutics, MAR 6, 2022, View Source [SID1234609531]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On March 4, 2022 OBiO Technology (Shanghai). a gene therapy company, reported that it signed a memorandum of understanding with Korea’s Eutilex to manufacture Eutilex’s cell therapy products in China (Press release, Eutilex, MAR 4, 2022, View Source [SID1234609543]). Eutilex’s portfolio includes innovative T cell, CAR-T cell and antibody therapies for cancer and autoimmune diseases. Eutilex plans to start clinical trials of its killer T-cell therapy (EBViNT) and its CAR-T therapy in China. OBiO will be responsible for building a GMP facility to manufacture viral vectors, tumor viruses and the company’s CAR-T in China.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On March 4, 2022 Coherus BioSciences, Inc. ("Coherus", Nasdaq: CHRS), reported that senior management will present at the following investor conferences in March (Press release, Coherus Biosciences, MAR 4, 2022, View Source [SID1234609533]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

42nd Annual Cowen Health Care Conference on Wednesday, March 9 at 10:30 a.m. ET
Barclays Global Healthcare Conference on Tuesday, March 15 at 2:35 p.m. ET
Audio webcasts of these presentations will be available on the investors’ page of the Coherus website at View Source Please access the website prior to the start of the presentation to ensure a timely connection to the webcast. Each webcast will be archived on the Coherus website for 30 days.

On March 4, 2022 Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, reported that it will host a live conference call and audio webcast on Friday, March 11, 2022 at 8:30 a.m. ET to report financial results for the full year ended December 31, 2021 and to provide a business overview (Press release, Bio-Path Holdings, MAR 4, 2022, View Source [SID1234609530]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the live conference call, please call (844) 815-4963 (domestic) or (210) 229-8838 (international) at least five minutes prior to the start time and refer to conference ID 5089985. A live audio webcast of the call will also be available on the Presentations section of the Company’s website, www.biopathholdings.com. An archived webcast will be available on the Bio-Path website approximately two hours after the event.

On March 4, 2022 Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), reported that Dr. Lishan Aklog, Chairman and CEO, will participate, in-person, at the LSI ’22 Emerging Medtech Summit on March 15-18, 2022, at the Waldorf Astoria, Monarch Beach Resort & Club in Dana Point, California (Press release, Lucid Diagnostics, MAR 4, 2022, View Source [SID1234609527]). Dr. Aklog will present on March 17 at 3:15 p.m. PT on Track 1 in the Pacific Ballroom which will be followed by one-hour Q&A breakout session. In addition, Dr. Aklog will participate in a "CEO Innovator Spotlight" panel taking place on March 16 at 8 p.m. on the Grand Terrace overlooking the evening reception.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!